Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Non-Current Liabilities (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $177.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 26.52% year-over-year to $177.5 million, compared with a TTM value of $177.5 million through Dec 2025, up 26.52%, and an annual FY2025 reading of $177.5 million, up 26.52% over the prior year.
  • Total Non-Current Liabilities was $177.5 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $162.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $177.5 million in Q4 2025 and bottomed at $37.9 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $89.5 million, with a median of $75.1 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 95.45% in 2022, then fell 21.05% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $47.5 million in 2021, then rose by 29.88% to $61.7 million in 2022, then soared by 38.81% to $85.6 million in 2023, then soared by 63.85% to $140.3 million in 2024, then increased by 26.52% to $177.5 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for KNSA at $177.5 million in Q4 2025, $162.4 million in Q3 2025, and $156.9 million in Q2 2025.